Royalty Report: Drugs, Addiction, Drug Discovery – Collection: 356976

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 13

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 13

Primary Industries

  • Drugs
  • Addiction
  • Drug Discovery
  • Pharmaceuticals
  • Medical
  • Pain
  • Delivery
  • Therapeutic
  • Technical Know How
  • Ulcer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 356980

License Grant
With this fourth amendment to the Agreement the Licensor of Finland and Licensee of Denmark desire to remove all territorial restrictions for Licensees rights under the Agreement.  The original license is exclusive.
License Property
The compound is Nalmefene, a specific opioid receptor antagonist.

Nalmefene is an opioid antagonist used primarily in the management of alcohol dependence. It has also been investigated for the treatment of other addictions such as pathological gambling. Nalmefene is an opiate derivative similar in both structure and activity to the opioid antagonist naltrexone.

Field of Use
The field of use is for the treatment of substance abuse disorders such as alcoholism and obsessive compulsive disorders, including but not limited to pathological gambling.

IPSCIO Record ID: 356979

License Grant
With this second amendment the Licensor of Finland and the Licensee of Denmark desire to extend the geographical territory of Lundbecks rights under the Agreement to cover also the United States, Canada, Mexico and their territories and possession, including, but not limited to, the Commonwealth of Puerto Rico, and agree on certain arrangements related thereto.  The original agreement is exclusive.
License Property
The compound is Nalmefene, a specific opioid receptor antagonist.

Nalmefene is an opioid antagonist used primarily in the management of alcohol dependence. It has also been investigated for the treatment of other addictions such as pathological gambling. Nalmefene is an opiate derivative similar in both structure and activity to the opioid antagonist naltrexone.

Field of Use
The field of use is for the treatment of substance abuse disorders such as alcoholism and obsessive compulsive disorders, including but not limited to pathological gambling.

IPSCIO Record ID: 356976

License Grant
With this sixth amendment to the Agreement the Licensor of Finland and Licensee of Denmark wish to change the agreed royalty rates.
License Property
The compound is Nalmefene, a specific opioid receptor antagonist.

Nalmefene is an opioid antagonist used primarily in the management of alcohol dependence. It has also been investigated for the treatment of other addictions such as pathological gambling. Nalmefene is an opiate derivative similar in both structure and activity to the opioid antagonist naltrexone.

Field of Use
The field of use is for the treatment of substance abuse disorders such as alcoholism and obsessive compulsive disorders, including but not limited to pathological gambling.

IPSCIO Record ID: 356977

License Grant
Licensor of Finland grants to Licensee of Denmark an exclusive, sub-licensable license under the Licensed IP to Develop, have Developed, make, have made, use, have used, Commercialize and have Commercialized the Compound and Product for any purpose and for the therapy or prophylaxis of all disorders in the Territory. Further, Licensee shall have the right to perform Development activities outside the Territory for the purpose of obtaining Marketing Authorizations or increasing market potential of Product.

Licensor grants an exclusive, sub-licensable license to use for the Commercialization of Products in the Territory the trademarks used for products containing Compound by its distributor in the United Kingdom and Ireland.

License Property
Licensor has researched in and developed Nalmefene for dependence disorders, such as alcohol dependence and impulse control disorders, for which Licensor has obtained certain patents, know-how and conducted or sponsored certain studies.

Compound means the compound known as Nalmefene Hydrocloride (INN), and, including all chelates, complex conformers, crystal modifications, esters enantiomers, free acid, free base, isomers, isotopic or radio-labelled equivalent, metabolites, whether active or inactive, prodrugs other salts, solvates and stereoisomers thereof.

Nalmefene is an opioid antagonist used primarily in the management of alcohol dependence. It has also been investigated for the treatment of other addictions such as pathological gambling. Nalmefene is an opiate derivative similar in both structure and activity to the opioid antagonist naltrexone.

The trademarks include Soberal and Zenofene.

Field of Use
The commercialization is for any purpose and for the therapy or prophylaxis of all disorders in the Territory.  Nalmefene for dependence disorders.

The Licensee is a biopharmaceutical company primarily focused on developing therapeutics for central nervous system disorders.

IPSCIO Record ID: 356978

License Grant
This first amendment between the Licensor of Finland and the Licensee of Denmark modifies the territory and the royalties.  The original agreement is exclusive.
License Property
The original agreement is for the compound known as Nalmefene Hydrocloride (INN), and, including all chelates, complex conformers, crystal modifications, esters enantiomers, free acid, free base, isomers, isotopic or radio-labelled equivalent, metabolites, whether active or inactive, prodrugs other salts, solvates and stereoisomers thereof.

Nalmefene is an opioid antagonist used primarily in the management of alcohol dependence. It has also been investigated for the treatment of other addictions such as pathological gambling. Nalmefene is an opiate derivative similar in both structure and activity to the opioid antagonist naltrexone.

Field of Use
Nalmefene for dependence disorders.

IPSCIO Record ID: 336370

License Grant
Licensor grants an exclusive license under the Licensed Know-How and the Licensed Patents, to make, have made, use, import, sell, and offer for sale Licensed Compounds and Licensed Products in the Territory.
License Property
The Licensed Compound shall mean the compound known as OpRA Ill or xx-2136231 and all pharmaceutically acceptable salts, enantiomers, racemates, diastereomers, or mixtures thereof.

OpRA III is a potent opioid receptor antagonist, with potential use in multiple therapeutic indications.  Licensee believes OpRA III has a unique profile with the potential to address the gastrointestinal disorders.

Field of Use
The Field of Use means all therapeutic, prognostic and diagnostic indications and pharmaceutical applications for human and non-human purposes other than, prior to an OpRA II Termination Event, the treatment of substance abuse disorders, and impulse control disorders.

Licensee intends to initially develop OpRA III to treat opioid bowel dysfunction (OBD).

IPSCIO Record ID: 4464

License Grant
The Company shall grant the Licensee, for the territory, an exclusive License to use and distribute the Counseling Programs and certain products, including the Naltrexone Implant, constituting theLicensor Private Alcohol Rehabilitation Program.
License Property
The Licensor is involved in establishing alcohol rehabilitation and treatment center and has created certain alcohol therapeutic and rehabilitation programs (the Counseling Programs) consisting of a Naltrexone implant that is placed under the skin in the lower abdomen coupled with life counseling sessions from specialized counselors.

The Licensor has developed and owns worldwide rights to the Fresh Start Private Alcohol.

The Naltrexone implant is a special formulation of Naltrexone, which is designed to release slowly over a 6-12 week period. It is placed under the patient's skin and so it is effective and does not allow the patient to forget or skip their medicine.

Naltrexone is a pure narcotic antagonist. It attaches to the endorphin or opiate receptors in the brain and completely blocks them. This means that if someone tries to use any kind of opiate while they are on Naltrexone, they feel no effect because all of the receptors are completely blocked. While Naltrexone is in the body, it is virtually impossible to relapse.

Field of Use
The Field of Use is certain alcohol therapeutic and rehabilitation programs.

IPSCIO Record ID: 7531

License Grant
The Licensor shall grant to the Licensee an exclusive License for the territory consisting of the forty-eight most northern counties of the state of California, to use and distribute the Counseling Programs and certain products, including the Naltrexone Implant.
License Property
The Licensor provides an innovative alcohol treatment program that empowers patients to succeed in their overall recovery. We offer a unique treatment philosophy that combines medical intervention, a singular focus and a comprehensive approach, and a focus on family and friends.

The Licensor has developed and owns worldwide rights to the Fresh Start Private Alcohol.

The Naltrexone implant is a special formulation of Naltrexone, which is designed to release slowly over a 6-12 week period. It is placed under the patient's skin and so it is effective and does not allow the patient to forget or skip their medicine.

Naltrexone is a pure narcotic antagonist. It attaches to the endorphin or opiate receptors in the brain and completely blocks them. This means that if someone tries to use any kind of opiate while they are on Naltrexone, they feel no effect because all of the receptors are completely blocked. While Naltrexone is in the body, it is virtually impossible to relapse.

Field of Use
The Field of Use is an alcohol treatment program.

IPSCIO Record ID: 28536

License Grant
We entered into a Technology Purchase and License Agreement (Technology Agreement) with a Spanish corporation (Seller), to acquire, on an exclusive basis, all of the rights, title and interest to use and or sell the products and services and license the intellectual property owned by Seller with respect to a method for the treatment of alcohol and cocaine dependence, known as the PROMETA protocols, on a worldwide basis except in Spain (as amended in September 2003).
License Property
Seller is the rightful owner of certain technology, patents pending, know-how and related intellectual property with respect to an alcohol and cocaine detoxification and neuron adaptation process.

Much of our proprietary, patented and patent pending substance dependence technology, known as the Prometa treatment protocols, was developed by Dr. Juan José Legarda, a European scientist educated at University of London who has spent most of his professional career conducting research related to substance abuse. Through his studies and research, Dr. Legarda identified some of the adverse physical effects of substance abuse on the brain and began to develop technologies that specifically focused on the neurochemistry of the brain as a core part of addictive behavior modification. In 2002, Dr. Legarda filed Patent Cooperation Treaty (PCT) applications in Spain for treatment protocols that he developed for dependencies to alcohol and cocaine. We acquired the rights to these patent filings in March 2003 through a technology purchase and License Agreement with Dr. Legarda’s company, to which we pay a royalty of three percent of the amount the patient pays for treatment using our protocols.

Field of Use
Field of use The Intellectual Property may only be used to perform detoxification processes on persons for alcohol and/or cocaine addiction.

Unlike traditional treatment methodologies, our proprietary Prometaâ„¢ treatment protocols include medically supervised treatments designed to address both the neurochemical imbalances in the brain and some of the nutritional deficits caused or worsened by substance dependence. Changes in brain chemistry and function play an important role in the physical and behavioral symptoms of substance dependence, including tolerance, withdrawal symptoms, craving and relapse. Prometa represents an innovative approach to managing substance dependence that is designed to address physiological, nutritional and psychosocial aspects of the disease, and is thereby intended to offer patients an opportunity to achieve sustained recovery.

IPSCIO Record ID: 96463

License Grant
The Irish Licensor granted an exclusive license to utilize the Technology in developing injectable naltrexone products to treat patients suffering addiction to opioids, methamphetamines, cocaine, or alcohol.  The grant permits the Licensee to sell the products that utilize the Technology.
License Property
The licensor has know-how and patents related to sustained release drug delivery technology.
Field of Use
Licensee distributes and licenses a recovery program for alcoholism and opioid addiction treatment that empowers patients to succeed in their overall recovery.

IPSCIO Record ID: 2912

License Grant
The Licensor entered into a license and commercialization agreement with the Swiss Licensee to commercialize Vivitrol for the treatment of alcohol dependence and opioid dependence in Russia and other countries in the Commonwealth of Independent States.  Under the terms of the agreement, the Licensee has primary responsibility for securing all necessary regulatory approvals for Vivitrol and the Licensee's affiliate commercializes the product effective March 2009. The Licensor is responsible for the manufacture of Vivitrol and receives manufacturing and royalty revenues based upon product sales.  Vivitrol is the first and only once-monthly injectable medication for the treatment of alcohol dependence.
License Property
VIVITROL is an extended-release Medisorb formulation of naltrexone. VIVITROL is the first and only once-monthly injectable medication for the treatment of alcohol dependence. Alcohol dependence is a serious and chronic brain disease characterized by cravings for alcohol, loss of control over drinking, withdrawal symptoms and an increased tolerance for alcohol.
Field of Use
In August 2008, the Russian regulatory authorities approved Vivitrol for the treatment of alcohol dependence.

IPSCIO Record ID: 140394

License Grant
Under the terms of the agreement,Licensor has agreed to manufacture and supply the Company with COC-AB (Fab)2 product. As part of the relationship, Licensor has agreed to certain exclusivity provisions that preclude Licensor from developing, manufacturing or licensing a product that contains an anti-cocaine antibody or antibody derivative for anyone other than the Company. The Company has agreed to exclusively use Licensorr to manufacture COC-AB.
License Property
COC-AB is a biopharmaceutical product that address key medical needs of alcohol abusers and drug addicts.
Field of Use
This agreement pertains to the drug industry relating for the treatment of cocaine overdose and addiction.

IPSCIO Record ID: 372413

License Grant
The Licensor Parties grant an exclusive, world-wide license to make, have made, use, lease, import, offer for sale and sell Licensed Products and to use the method under Patent Rights and Technical information, to the extent not prohibited by other patents, in the Field of Use.
License Property
The Licensor Parties are the owners of the Method Patent and a pending patent entitled Treatment of Inflammatory and Ulcerative Diseases of the Bowel with Opioid Antagonists and one Licensor is the owner/Sponsor of IBD FDA IND#, FDA orphan drug designation x-2969 and a pending patent for Treatment of Inflammatory and Ulcerative Diseases of the Bowel with Opioid Antagonists.
Field of Use
The term Field of Use means development, production, use, and storage of Licensed Products, alone or in combination with other treatments, for the prevention and/or treatment of Crohn's disease and other inflammatory and ulcerative diseases of the bowel.
Crohn's disease is a type of inflammatory bowel disease (IBD) that may affect any segment of the gastrointestinal tract from the mouth to the anus
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.